Abstract
Hypertriglyceridemia is an important risk factor for the development of coronary artery disease and is associated with insulin resistance. The aim of the present work was to study effects of the hypolipidemic drug acipimox (lipolysis inhibitor) in hypertriglyceridemic middle aged persons using Bergman's minimal model method.
The frequent sampling intravenous tolerance test (FSIGT) was performed in 7 hypertriglyceridemic men (age 44.0 +- 1.0 years, BMI 28.42 +- 1.64 kg/m2) before and after 8 weeks of acipimox therapy (250 mg 3 times daily). Index K(G) improved (2.49 +- 0.46 and 3.25 +- 0.30% min-1, p<0.05) and the area under the glucose curve too (372.1 +- 38.6 and 291.2 +- 27.1 mmol.min/l, p<0.05)).
Acipimox treatment increased glucose effectiveness S(G) (2.15 +- 0.22 and 3.32 +- 0.48 l/min. 102, p<0.05) and GEZI (1.87 +- 0.22 and 2.98 +- 0.42 l/min. 102, p<0.05). Insulin sensitivity S(I), first (Φ1) and second (Φ2) phase of insulin secretion, was unchanged.
We conclude, that the lipolysis inhibitor, acipimox, had a favourable effect on glucose effectiveness and improved glucose tolerance.